The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
Open accessPublished version of a preprint
Abstract
BACKGROUND: The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known. METHODS: In this ongoing, phase 2-3 study, we compared the 50-μg bivalent vaccine mRNA-1273.214 (25 μg each of ancestral Wuhan-Hu-1 and omicron B.1.1.529 [BA.1] spike messenger RNAs) with the previously authorized 50-μg mRNA-1273 booster. We administered mRNA-1273.214 or mRNA-1273 as a second booster in adults who had previously received a two-dose (100-μg) primary series and first booster (50-μg) dose of mRNA-1273 (≥3 months earlier). The primary objectives were to assess the safety, reactogenicity, and immunogenicity of mRNA-1273.214 at 28 days after the booster dose. RESULTS: Interim results are presented. Sequential groups of participants received 50 μg of mRNA-1273.214 (437 participants) or mRNA-1273 (377 participants) as a second booster dose. The median time between the first and second boosters was similar for mRNA-1273.214 (136 days) and mRNA-1273 (134 days). In participants with no previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the geometric mean titers of neutralizing antibodies against the omicron BA.1 variant were 2372.4 (95% confidence interval [CI], 2070.6 to 2718.2) after receipt of the mRNA-1273.214 booster and 1473.5 (95% CI, 1270.8 to 1708.4) after receipt of the mRNA-1273 booster. In addition, 50-μg mRNA-1273.214 and 50-μg mRNA-1273 elicited geometric mean titers of 727.4 (95% CI, 632.8 to 836.1) and 492.1 (95% CI, 431.1 to 561.9), respectively, against omicron BA.4 and BA.5 (BA.4/5), and the mRNA-1273.214 booster also elicited higher binding antibody responses against multiple other variants (alpha, beta, gamma, and delta) than the mRNA-1273 booster. Safety and reactogenicity were similar with the two booster vaccines. Vaccine effectiveness was not assessed in this study; in an exploratory analysis, SARS-CoV-2 infection occurred in 11 participants after the mRNA-1273.214 booster and in 9 participants after the mRNA-1273 booster. CONCLUSIONS: The bivalent omicron-containing vaccine mRNA-1273.214 elicited neutralizing antibody responses against omicron that were superior to those with mRNA-1273, without evident safety concerns. (Funded by Moderna; ClinicalTrials.gov number, NCT04927065.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, modified bivalent mRNA SARS-CoV-2 vaccines elicited significantly higher nAb responses against recent SARS-CoV-2 variants and non-inferior titres against ancestral virus compared with monovalent vaccines in humans and preclinical animal models9,24.”
From Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models (2023) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results are similar to the neutralizing antibody titer ratios observed with the other approved BA.1-adapted mRNA vaccines when compared with their prototype vaccines.”
From An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial (2024) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Neutralizing antibody response is considered to be a surrogate for efficacy against severe disease24 and has been used in immunobridging studies, especially for variant-updated COVID-19 vaccines20.”
From An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial (2024) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×
“3 months following the 2-dose 100-μg primary series immunization in the coronavirus efficacy (COVE) trial.(1,2) Soon after the beginning of the SARS-CoV-2 pandemic, several variants with spike protein mutations that can confer immunologic escape or enhanced transmissability have emerged, such as the beta (B.”
BackgroundSelf-citationKhoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et al. (2022) · Nature · doi:10.1038/s41586-022-04980-y · Cited by 1,306
Self-citationImmune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Gilbert, P. B., Montefiori, D. C., McDermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., et al. (2022) · Science · doi:10.1126/science.abm3425 · Cited by 1,137
Self-citationIncreased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641
Self-citationEffectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O'Dell, S. J., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 447
Self-citationFerdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7107e2 · Cited by 435
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
Wu, K., Werner, A. P., Koch, M., Choi, A., Narayanan, E., Stewart-Jones, G. B. E., Colpitts, T., Bennett, H., Boyoglu-Barnum, S., Shi, W., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102179 · Cited by 409
Self-citationThompson, M. G., Natarajan, K., Irving, S. A., Rowley, E. A., Griggs, E. P., Gaglani, M., Klein, N. P., Grannis, S. J., DeSilva, M. B., Stenehjem, E., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7104e3 · Cited by 398
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
Suryawanshi, R. K., Chen, I. P., Ma, T., Syed, A. M., Brazer, N., Saldhi, P., Simoneau, C. R., Ciling, A., Khalid, M. M., Sreekumar, B. K. N., et al. (2022) · Nature · doi:10.1038/s41586-022-04865-0 · Cited by 208
Chalkias, S., Eder, F. S., Essink, B. J., Khetan, S. K., Nestorova, B., Feng, J., Chen, X., Chang, Y., Zhou, H., Montefiori, D. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02031-7 · Cited by 131
Self-citationCarazo, S., Skowronski, D. M., Brisson, M., Sauvageau, C., Brousseau, N., Gilca, R., Ouakki, M., Barkati, S., Fafard, J., Talbot, D. C., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00578-3 · Cited by 111
Chu, L., Montefiori, D., Huang, W., Nestorova, B., Chang, Y., Carfi, A., Edwards, D. K., Oestreicher, J., Legault, H., Girard, B., et al. (2021) · doi:10.1101/2021.09.29.21264089 · Cited by 105
Self-citationBA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infectionPreprint
Cao, Y., Yisimayi, A., Jian, F., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.30.489997 · Cited by 90
Tang, J., Novak, T., Hecker, J., Grubbs, G., Zahra, F. T., Bellusci, L., Pourhashemi, S., Chou, J. S., Moffitt, K. L., Halasa, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30649-1 · Cited by 55
Prasad, N., Derado, G., Nanduri, S. A., Reses, H. E., Dubendris, H., Wong, E., Soe, M. M., Li, Q., Dollard, P., Bagchi, S., et al. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7118a4 · Cited by 44
Multiple Endpoints in Clinical Trials
Weissfeld, L. A. (2014) · Wiley StatsRef: Statistics Reference Online · doi:10.1002/9781118445112.stat04948 · Cited by 33
mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children
Girard, B., Tomassini, J. E., Deng, W., Maglinao, M., Zhou, H., Figueroa, A., Ghamloush, S. S., Montefiori, D. C., Das, R., & Pajon, R. (2022) · doi:10.1101/2022.01.24.22269666 · Cited by 23
Self-citationSafety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccinePreprint
Chalkias, S., Eder, F. S., Essink, B. J., Khetan, S. K., Nestorova, B., Feng, J., Chen, X., Chang, Y., Zhou, H., Montefiori, D. C., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1555201/v1 · Cited by 22
Self-citationCovid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant SurgePreprint
Baden, L. R., Sahly, H. M. E., Essink, B. J., Follmann, D. A., Neuzil, K. M., August, A., Clouting, H., Fortier, G., Deng, W., Han, S., et al. (2021) · medRxiv · doi:10.1101/2021.09.17.21263624 · Cited by 21
Self-citation
Research works printed but not linked: 4
- 10.1126/science.abn4947 · DOI · Paper page
- 10.1038/s41591-022-01739-w · DOI · Paper page
- 10.1038/s41591-022-01753-y · DOI · Paper page
- Carazo S Skowronski DM Brisson M et al. Protection against omicron re-infection conferred by prior heterologous SARS-CoV-2 infection with and without mRNA vaccination. May 3 2022 (https://www.medrxiv.org/content/10.1101/2022.04.29.22274455v2). preprint. · DOI
Cited by
Sorted by citations
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults
Wilson, E. M. P., Goswami, J., Baqui, A. H., Doreski, P. A., Marc, G. P., Zaman, K., Monroy, J., Duncan, C. J. A., Ujiie, M., Rämet, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307079 · Cited by 544
Self-citationShrestha, L. B., Foster, C. S. P., Rawlinson, W. D., Tedla, N. T., & Bull, R. A. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2381 · Cited by 483
Chatterjee, S., Bhattacharya, M., Nag, S., Dhama, K., & Chakraborty, C. (2023) · Viruses · doi:10.3390/v15010167 · Cited by 325
Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity: A Systematic Review and Meta-analysis
Menegale, F., Manica, M., Zardini, A., Guzzetta, G., Marziano, V., d'Andrea, V., Trentini, F., Ajelli, M., Poletti, P., & Merler, S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.10650 · Cited by 280
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
Davis-Gardner, M. E., Lai, L., Wali, B., Samaha, H., Solis, D., Lee, M., Morrison-Porter, A., Hentenaar, I., Yamamoto, F. F., Godbole, S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2214293 · Cited by 254
Metadata
- Authors
- Chalkias, S., Harper, C., Vrbicky, K., Walsh, S. R., Essink, B., Brosz, A., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., Sutherland, A., Montefiori, D. C., Girard, B., Edwards, D. K., Feng, J., Zhou, H., Baden, L. R., Miller, J. M., & Das, R.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Chalkias, Spyros
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-10-06
- Volume
- 387
- Issue
- 14
- Pages
- 1279-1291
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC9511634
- OpenAlex
- W4296026861
- Cited by
- 627
- References
- 24
- Citations by year
- 2026: 29 · 2025: 74 · 2024: 163 · 2023: 276 · 2022: 83
- FWCI
- 72.71
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Moderna
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- Omicron variant, BA.1, neutralizing antibodies, vaccine immunogenicity, vaccine safety, reactogenicity, SARS-CoV-2 infection history
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, 2019-nCoV Vaccine mRNA-1273, Adult, Antibodies, Viral, Humans, Immunization, Secondary, Vaccines, Combined, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
